Acute myeloid leukemia
Conditions
Brief summary
Ratio of dose delivered/dose planned over the 12-cycle treatment period as evaluated at 12 months. This endpoint reflects both treatment efficacy (patients live longer event-free), and safety (less dose reductions, less omitted doses)
Detailed description
Ratio of dose delivered/dose planned over 2 cycles evaluated after 75 days, Complete hematologic remission/complete remission with partial hematologic recovery (CR/CRh), DOR, RFS, OS, CIR, Depth of response by MRD, Tolerability (Adverse events), Duration of cytopenias, transfusion dependence
Interventions
Sponsors
Technische Universitat Dresden
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio of dose delivered/dose planned over the 12-cycle treatment period as evaluated at 12 months. This endpoint reflects both treatment efficacy (patients live longer event-free), and safety (less dose reductions, less omitted doses) | — |
Secondary
| Measure | Time frame |
|---|---|
| Ratio of dose delivered/dose planned over 2 cycles evaluated after 75 days, Complete hematologic remission/complete remission with partial hematologic recovery (CR/CRh), DOR, RFS, OS, CIR, Depth of response by MRD, Tolerability (Adverse events), Duration of cytopenias, transfusion dependence | — |
Countries
Germany
Outcome results
None listed